A Pennsylvania nonprofit helping to bolster breast cancer research is offering welcome funding to a Pitt doctor interested in the role of artificial intelligence in disease detection.
Amid a swath of federal funding freezes and cuts threatening to gut millions in grant money across city institutions including the University of Pittsburgh, the Pennsylvania Breast Cancer Coalition awarded $100,000 to radiology professor and UPMC Hillman Cancer Center researcher Dr. Shandong Wu and co-principal investigator Dr. Marija Balic to study how artificial intelligence can help predict breast cancer recurrence and identify optimal patients for a certain breast cancer treatment.
“Now more than ever, this kind of support is critical as we face uncertainty around research funding,” said Jennifer Pensinger, executive director of the Pennsylvania Breast Cancer Coalition, on Thursday during a news conference at the UPMC Hillman Cancer Center, where the check was presented to Dr. Wu and his team. “The future of many promising projects just hangs in the balance.”
Dr. Wu said he has been working on this area in his research for nearly 15 years.
“We are so lucky to get funded,” he said. “My lab members are here, and they’re doing important work to translate the power of AI and technology to cure diseases like breast cancer.”
The Pennsylvania Breast Cancer Coalition has been awarding the state’s scientists funding annually since 1997, totaling $6.1 million in grants, with the goal of advancing breast cancer research and ultimately finding a cure.
Read More
This year, scientists received $500,000 in funding from the nonprofit: Additional awards went to researchers at Penn Medicine, Pennsylvania State University Hershey and Thomas Jefferson University.
Dr. Wu also won a $100,000 grant from the coalition in 2024. The grants last one year.
That Dr. Wu is a two-time recipient of the competitive application program is “a testament to his ongoing commitment to improving breast cancer detection in research,” said Ms. Pensinger.
“They’re doing incredible work here,” echoed Natalie Kopp, the coalition’s communications director.
More than 13,000 Pennsylvania women are diagnosed with breast cancer every year, and 2,000 die from it. Breast cancer rates for women in the state are slightly higher than the national average, at 131.2 cancers per 100,000, compared to the national average of 129.8 cancers per 100,000, according to National Cancer Institute data.
The death rate for Pennsylvania women is also higher than the U.S. average, though Allegheny County data indicates that breast cancer incidence rates are steady.
Drs. Wu and Balic’s research has the capability of impacting countless women throughout Pennsylvania and beyond, said Ms. Kopp.
Artificial intelligence has taken a front seat in the public eye in the past year or so with the explosive popularity of OpenAI’s ChatGPT.
In medicine and research generally, AI can ease administrative tasks and help researchers find patterns in massive datasets. Many researchers in biology, neuroscience and cancer labs use machine learning to parse through genetic code or identify at-risk indicators from de-identified patient data.
Dr. Wu’s plan is to take advantage of the large amount of data hospitals already maintain on their patients — such as diagnoses, imaging and bloodwork — and build an AI learning model to better detect the likelihood that a patient’s breast cancer may recur.
Those at risk of recurrence have a few options: more chemotherapy, surgery or medications. Tamoxifen is one of those treatments, a medicine used to treat hormone-receptor-positive breast cancer, that helps reduce the likelihood of cancer recurrence by blocking estrogen activity and thus preventing cancer cell growth.
The medication needs to be taken for five to 10 years and, because of side effects that include muscle stiffness, hot flashes, intense changes in mood and trouble sleeping, adherence to the medication can be low.
One 2017 study published in the British Journal of Health Psychology found that only 50% of patients reported adhering to their Tamoxifen prescription by the fifth year of treatment.
Dr. Wu and his lab want to use AI modeling to better understand who will respond to treatment like Tamoxifen and who may not — sparing them years of time on the medicine and its burdensome side effects.
Last year, Dr. Wu used the grant money to help pay the stipends of lab technicians working on these projects, enabling them to stay in the lab. He also used some of the money to pay for the fees of data collection.
He’s looking forward to partnering with Dr. Balic, co-director of UPMC Magee-Womens Cancer Program, who moved to the United States from Austria in 2024 to work at UPMC. Collaboration between researchers and clinicians is critical to translating lab projects to patients on the ground, the pair said.
“At UPMC Hillman Cancer Center, we’re promoting collaboration and multi-disciplinary research, so that we can … really address those real-world challenges,” said Dr. Wu.
His team is navigating the challenges and uncertainty of the past few months, he said, with the fate of federal research grants dangling, and that a grant like this from the Pennsylvania Breast Cancer Coalition helps them continue during uncertain times.
“These are projects that lead to breakthroughs in screenings, treatment and ultimately a cure,” said Ms. Pensinger. “That’s why we are so passionate about funding research, even if our part is small.”
Dr. Wu countered: No contribution, in these times, is small.
“This is very important support for us as researchers,” he said. “Every dollar counts.”






Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.